Pankaj Bhargava was a central figure in the group fashioning Gilead’s oncology strategy. Now he’s jumped to the VC side and the next-gen game at Dana-Farber
Over the past 3 years, Pankaj Bhargava played a key role at Gilead as therapeutics area head of oncology, which put him in the dead center of one of the busiest pipeline makeovers in the industry.
“When I joined (the big biotech), there was a clear realization that Gilead had missed the first boat with immuno-oncology,” he tells me. “We hadn’t gone into the PD-1s, the checkpoints, etc. They had just bought Kite and the question was how do we get into oncology.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.